OncoMatch/Endometrial / Uterine Cancer/PIK3CA

Endometrial / Uterine CancerPIK3CA Clinical Trials

2 recruiting trials·Updated daily from ClinicalTrials.gov

PIK3CA activating mutations are among the most frequent alterations in endometrial cancer (~50% of endometrioid subtype) and activate the PI3K/AKT/mTOR pathway, which is a central therapeutic axis in this disease. mTOR inhibitors (lenvatinib plus everolimus) and AKT inhibitors (capivasertib) have demonstrated activity in endometrial cancer. Trials evaluate PI3K/AKT/mTOR-directed combinations and biomarker-stratified approaches for pMMR endometrial cancer.

Match trials to my profile Clinician mode →

Top recruiting

Top recruiting PIK3CA Endometrial / Uterine Cancer trials

Ranked by phase and US site count.

See all trials matched to your profile →

Phase 1/Phase 214 US sites

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Terremoto Biosciences Inc.

Phase 11 US site

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

M.D. Anderson Cancer Center

Other Endometrial / Uterine Cancer biomarkers

Browse other molecular targets with active Endometrial / Uterine Cancer trials.

MMR / MSI-H POLE (ultramutated)PD-L1 (CD274)

← All Endometrial / Uterine Cancer clinical trials